Abstract
Background:With an estimated 174 million undiagnosed cases of diabetes mellitus worldwide and 80% of them occurring in low- and middle-income countries an effective point-of-care diagnostic tool is key to fighting this global epidemic. Glycated hemoglobin has become a reliable biomarker for the diagnosis and prognosis of diabetes.Objective:We assessed two point-of-care (POC) analyzers in multi-ethnic communities of the Amazon Rainforest in Peru where laboratory-based glycated hemoglobin (HbA1c) testing is not available.Methods:203 venous blood samples were tested for HbA1c by Afinion and DCA Vantage analyzers as well as a Premier Hb9210 high-performance liquid chromatography (HPLC) method as the reference standard. The coefficient of variation (CV) of each device was calculated to assess assay imprecision. Bland-Altman plots were used to assess bias. Ambient temperature, humidity, and barometric pressure were also evaluated for their effect on HbA1c results using multivariate regression.Findings:There was a wide range of HbA1c for participants based on the HPLC test: 4.4–9.0% (25–75 mmol/mol). The CV for the Afinion was 1.75%, and 4.01% for Vantage. The Afinion generated higher HbA1c results than the HPLC (mean difference = +0.56% [+6 mmol/mol]; p < 0.001), as did the DCA Vantage (mean difference = +0.32% [4 mmol/mol] p < 0.001). Temperature and humidity were not related to HbA1c; however, barometric pressure was associated with HPLC HbA1c results for the Afinion.Conclusions:Imprecision and bias were not low enough to recommend either POC analyzer for HbA1c determinations in this setting.
Highlights
With an estimated 174 million undiagnosed cases of diabetes mellitus worldwide and 80% of them occurring in low- and middle-income countries an effective point-of-care diagnostic tool is key to fighting this global epidemic
Questions remain as to how accurate they perform in different environments, in low- and middle-income countries (LMICs) settings where environmental conditions are less controllable than a clinical laboratory
HbA1c results using the Afinion and DCA Vantage POC analyzers and the Premier Hb9210 high-performance liquid chromatography (HPLC) analyzer were obtained for 203 individuals. 137 participants were female (72%) with an average age of 36.6 years
Summary
With an estimated 174 million undiagnosed cases of diabetes mellitus worldwide and 80% of them occurring in low- and middle-income countries an effective point-of-care diagnostic tool is key to fighting this global epidemic. Objective: We assessed two point-of-care (POC) analyzers in multi-ethnic communities of the Amazon Rainforest in Peru where laboratory-based glycated hemoglobin (HbA1c) testing is not available. Methods: 203 venous blood samples were tested for HbA1c by Afinion and DCA Vantage analyzers as well as a Premier Hb9210 high-performance liquid chromatography (HPLC) method as the reference standard. In addition to blood glucose measurements, one of the methods for diagnosing and managing diabetes is to analyze glycated hemoglobin (HbA1c) using laboratory-based instruments such as highperformance liquid chromatography (HPLC). Point-of-care (POC) analyzers have been developed that allow healthcare providers to obtain rapid HbA1c results on-site with significantly fewer logistical challenges as the HPLC method. Questions remain as to how accurate they perform in different environments, in LMIC settings where environmental conditions are less controllable than a clinical laboratory
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
